SECsense Logo

Tonix Pharmaceuticals 8-K Report: Key Insights for Investors - December 2024

$TNXP
Form 8-K
Filed on: 2024-12-17
Source
Tonix Pharmaceuticals 8-K Report: Key Insights for Investors - December 2024

Based on the extracted XML data from the financial report, here are the key insights and information:

  1. Entity Information:
  • Company Name: Tonix Pharmaceuticals Holding Corp.
  • CIK Number: 0001430306
  • Trading Symbol: TNXP
  • Exchange: NASDAQ
  • Address: 26 Main Street, Chatham, NJ 07928
  • Contact Number: 862-904-8182
  1. Filing Details:
  • Filing Type: 8-K
  • Filing Date: December 17, 2024
  1. Period of Reporting:
  • Report Date: The report covers the date December 17, 2024.
  1. Financial Measurements:
  • Currency: USD (U.S. Dollars)
  • Units of Measurement:
    • Financial figures are reported in USD.
    • Shares are used to denote stock-related metrics.
  1. Identifiers and Schema:
  • Schema Reference: The filing references a schema file (tnxp-20241217.xsd), which likely contains the detailed structure of the financial report.
  1. Miscellaneous Information:
  • The report indicates the company is involved with common stock trading.

Insights:

  • Market Position: Tonix Pharmaceuticals is publicly traded on NASDAQ under the ticker TNXP, indicating its status as a publicly-held company.
  • Regulatory Compliance: The filing of an 8-K suggests that the company is providing significant information that may be material to its investors, which is a standard practice for publicly traded companies.
  • Contact Information: The inclusion of a contact number and address provides transparency and accessibility for stakeholders.

This information is crucial for investors, analysts, and stakeholders looking to understand the company's current status, recent filings, and overall market presence.